Video

Dr. Govindan on the Genomic Characterization of Large-Cell Neuroendocrine Lung Tumors

Ramaswamy Govindan, MD, medical oncologist, Washington University School of Medicine in St. Louis, discusses a talk given at the 16th World Conference on Lung Cancer.

Ramaswamy Govindan, MD, medical oncologist, Siteman Cancer Center and Washington University School of Medicine in St. Louis, discusses a talk given at the 16th World Conference on Lung Cancer.

Govindan says he was struck by the fact that some samples of large-cell neuroendocrine lung tumors look like small cell lung cancer while others look like non-small cell lung cancer (NSCLC). These tumors typically present in smokers and lead to poor outcomes.

There remains a need, he says, to understand the biology of these cancers so they can be treated with biological and rational therapies.

<<<

View more from the 2015 World Conference on Lung Cancer

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD
Sally Lau, MD